Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) with a report date of November 8, 2016, covering an event that occurred on November 7, 2016. The filing serves as a Regulation FD disclosure regarding a scientific presentation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported in this document. The primary event is the presentation of a poster titled "Comprehensive In Vivo Nonclinical Safety Assessment of NSI-189, a Small Molecule New Chemical Entity for the Treatment of Major Depressive Disorder" at the 2016 American College of Toxicology Annual Meeting in Baltimore, Maryland.
Guidance, Outlook, and Risks
- Management Commentary: The company disclosed the presentation of nonclinical safety data for its drug candidate NSI-189.
- Legal Disclaimer: The information contained in this Item 7.01 and the attached exhibit is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
- Incorporation by Reference: The information shall not be deemed incorporated by reference in any filing under the Securities Act or Exchange Act unless expressly set forth by specific reference.
Investor Verification Checklist
- Verify the company name is Neuralstem, Inc., as the input metadata incorrectly listed Palisade Bio, Inc.
- Review Exhibit 99.01 (the poster) for specific nonclinical safety data details regarding NSI-189.
- Confirm that this disclosure does not constitute a formal filing of the scientific data under Section 18 of the Exchange Act.
- Note that no financial performance data is included in this specific 8-K filing.